
Investments
73Portfolio Exits
15Funds
1Partners & Customers
1About H.I.G. BioHealth Partners
H.I.G. BioHealth Partners invests in a broad range of life science opportunities across sectors and stages. The firm's seasoned investment team has extensive and diverse experience in big pharma, small biotech, medical devices, diagnostics, basic science, clinical research, and technology transfer. H.I.G. BioVentures invests in companies developing products for significant unmet medical needs, primarily in the following sectors: Therapeutics, Medical Devices, and Diagnostics.

Want to inform investors similar to H.I.G. BioHealth Partners about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest H.I.G. BioHealth Partners News
Mar 8, 2022
Previously, she worked at for Smith & Nephew’s U.S. robotics business unit where she was vice president and general manager. Email address I accept: Email address A link has been emailed to you - check your inbox. Sign in to your account Email address Nearly there! We have just sent you an email so you can verify your account. Please check your spam or junk folder just in case it’s been delivered there. If you do not receive this within five minutes, please try and sign in again. If the problem persists, please email: subscriptions@peimedia.com. Copyright PEI Media Share with other subscribers Cancel
H.I.G. BioHealth Partners Investments
73 Investments
H.I.G. BioHealth Partners has made 73 investments. Their latest investment was in Click Therapeutics as part of their Series B on October 10, 2021.

H.I.G. BioHealth Partners Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
10/22/2021 | Series B | Click Therapeutics | $52M | Yes | 15 | |
10/22/2020 | Series A - IV | Orbus Therapeutics | $10M | No | 1 | |
8/11/2020 | Series A - III | Orbus Therapeutics | $10M | No | 1 | |
7/20/2020 | Series F - II | |||||
5/26/2020 | Series A - II |
Date | 10/22/2021 | 10/22/2020 | 8/11/2020 | 7/20/2020 | 5/26/2020 |
---|---|---|---|---|---|
Round | Series B | Series A - IV | Series A - III | Series F - II | Series A - II |
Company | Click Therapeutics | Orbus Therapeutics | Orbus Therapeutics | ||
Amount | $52M | $10M | $10M | ||
New? | Yes | No | No | ||
Co-Investors | |||||
Sources | 15 | 1 | 1 |
H.I.G. BioHealth Partners Portfolio Exits
15 Portfolio Exits
H.I.G. BioHealth Partners has 15 portfolio exits. Their latest portfolio exit was Clarus Therapeutics on September 09, 2021.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
9/9/2021 | Reverse Merger | 3 | |||
7/30/2021 | IPO | Public | 2 | ||
1/4/2021 | Acquired | 18 | |||
Date | 9/9/2021 | 7/30/2021 | 1/4/2021 | ||
---|---|---|---|---|---|
Exit | Reverse Merger | IPO | Acquired | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 3 | 2 | 18 |
H.I.G. BioHealth Partners Fund History
1 Fund History
H.I.G. BioHealth Partners has 1 fund, including H.I.G. BioHealth Partners III.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
11/27/2019 | H.I.G. BioHealth Partners III | $128.75M | 1 |
Closing Date | 11/27/2019 |
---|---|
Fund | H.I.G. BioHealth Partners III |
Fund Type | |
Status | |
Amount | $128.75M |
Sources | 1 |
H.I.G. BioHealth Partners Partners & Customers
1 Partners and customers
H.I.G. BioHealth Partners has 1 strategic partners and customers. H.I.G. BioHealth Partners recently partnered with Vertiflex on March 3, 2017.
Date | Type | Business Partner | Country | News Snippet | Sources |
---|---|---|---|---|---|
3/15/2017 | Partner | United States | HIG BioHealth invests in VertiFlex Michael Wasserman , HIG managing director , says : `` We are excited to partner with the VertiFlex management team . | 1 |
Date | 3/15/2017 |
---|---|
Type | Partner |
Business Partner | |
Country | United States |
News Snippet | HIG BioHealth invests in VertiFlex Michael Wasserman , HIG managing director , says : `` We are excited to partner with the VertiFlex management team . |
Sources | 1 |
H.I.G. BioHealth Partners Team
1 Team Member
H.I.G. BioHealth Partners has 1 team member, including current Managing Director, Michael Wasserman.
Name | Work History | Title | Status |
---|---|---|---|
Michael Wasserman | Managing Director | Current |
Name | Michael Wasserman |
---|---|
Work History | |
Title | Managing Director |
Status | Current |
Compare H.I.G. BioHealth Partners to Competitors
Axela is delivering on its mission to provide a simple and effective approach to personalized medicine by exploiting the dotLab System in research markets today to generate tomorrow's diagnostics. This strategy of offering a common technology platform to both markets aims to provide a opportunity to capitalize on discoveries. The approach has already resulted in applications with the potential to address segments of the large, underserved markets of oncology and cardiology that will be the focus of two funded clinical trials this summer and growing installed customer base. For a time these leading clinical researchers can use the direct understanding of protein interactions to develop quantitative assays on a single platform. dot technology has shortened the transition from protein discovery to application. The ability to measure biomolecular complexes in real-time aims to provide for new approaches to disease management.
Informed Medical is an interactive medical information services provider that enables biopharmaceutical companies to market directly to physicians and patients.
Chalex Corporation's precision-made chambered McMaster counting slides are used by researchers, laboratories, nematologists and veterinary practitioners throughout the world. Made of clear durable acrylic for long-lasting use, the company's slides also feature exact volumes thanks to injection-molded accuracy which yield consistent test results compared to other slides with handmade chamber spacers. The quality of these slides make them the standard the world over.

Sage Science develops products for the life sciences research markets. Its mission is to provide new systems to streamline and improve sample preparation workflows for DNA and protein analysis.

Punjab Biotechnology Incubator (PBTI) welcomes users to its state-of-the- art Agri & Food Testing Laboratory set up at SAS Nagar (Mohali), the hub of Biotechnology and Information Technology in Punjab. PBTI is a State Govt. Undertaking registered as a "˜Society for Biotechnology Incubator' under the Society Registration Act 1961 and is professionally governed by Governing Council of the Society under the chairmanship of Chief Secretary, Govt. of Punjab. The day to day affairs are managed by Chief Executive Officer, supported by technical professionals of high caliber.
Laureate Pharma, Inc. is a full service contract manufacturing organization(CMO) providing development and cGMP manufacturing services in the company's FDA registered facilities in Princeton, New Jersey. The company is dedicated to supporting the development and commercialization of biopharmaceutical, drug and diagnostic products for pharmaceutical, diagnostic and biotech companies.The company aims to provide a range of product development and manufacturing services from cell line optimization and process design to development of full-scale cGMP protein production, purification and aseptic filling, in addition to corresponding testing, validation, analytical and regulatory support. The company's focus is on mammalian cell based monoclonal antibody and recombinant protein production for clinical and modest commercial supply.The company view the company's customers as partners and provide them with flexible solutions that reduce time to clinic and market. Focused on operational excellence, the company's highly experienced staff works with the company's customers to improve the quality of their products and processes.The company value the company's customers, stakeholders and associates. Therefore, the company measure the company's success by meeting the company's customers' needs, generating results in terms of quality, timeliness and on budget performance, as well as fostering an environment of trust, growth and diversity for the company's team.